Related Experiment Video
Updated: Oct 17, 2025
06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
435
Second primary malignancy among malignant solid tumor survivors aged 85 years and older
Zhijia Zhang1, Fei Liu1, Yanlin Qu2
1Department of Clinical Laboratory, The Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Scientific Reports
|October 6, 2021
Summary
Cancer survivors aged 85+ have a 5.3% incidence of second primary malignancy (SPM). Younger age and urinary system cancers increase SPM risk, while older age and male gender worsen survival outcomes.
Area of Science:
- Oncology
- Epidemiology
- Geriatric Medicine
Background:
- The cancer burden is increasing in the oldest old population.
- Understanding second primary malignancy (SPM) risk in this demographic is crucial.
Purpose of the Study:
- To investigate the epidemiology of SPM in malignant solid tumor survivors aged 85 years and older.
- To identify risk factors for SPM development and survival outcomes.
Main Methods:
- Utilized the Surveillance, Epidemiology, and End Results (SEER) database.
- Analyzed 128,466 malignant solid tumor patients diagnosed between 2000 and 2011.
- Included 6,774 patients who developed a SPM.
Main Results:
- Overall SPM incidence was 5.3%; 10-year cumulative incidence was 5.4%.
- Factors associated with higher SPM incidence include younger age, male gender, surgery history, local stage, and urinary system first primary malignancy.
- Median time to SPM diagnosis was 24 months. Digestive system was the most common SPM site.
- Median overall survival was 49 months; median survival post-SPM was 13 months.
- Older age, male gender, and black race were linked to worse survival.
Conclusions:
- This study provides a comprehensive epidemiological analysis of SPM in elderly cancer survivors (85+).
- Identified key risk factors for SPM development and prognostic indicators for survival.
- Further research is needed to characterize specific cancer types and inform targeted interventions.
More Related Videos
Related Concept Videos
02:07Tumor Progression
6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K
02:21Cancers Originate from Somatic Mutations in a Single Cell
13.2K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
13.2K
01:21Cancer Survival Analysis
481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K